Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of worsening heart failure events in adults with ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year ...

Worsening heart failure events occurred in 29 patients (8.0%) in the tirzepatide group compared to 52 (14.2%) in the placebo group, representing a 46% reduction in risk for those taking tirzepatide.

On the primary endpoints of the study, combined cardiovascular mortality and worsening heart failure events (α = 0.04) were determined in 36 patients (9.9%) in the tirzepatide group, whereas in ...

Treatment with tirzepatide was associated with a reduction in the risk of heart failure (HF) outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

Tirzepatide shows ‘practice-changing’ CV benefits for obesity-related heart failure. ... treatment with tirzepatide cut risk for CV death or worsening HF by 38% compared with placebo, ...

Tirzepatide showed a 38% reduction in the risk of heart failure outcomes, assessed as a composite endpoint, compared to placebo. Risk of hospitalization for heart failure was reduced by 56%.

"Cardiometabolic diseases, such as heart failure and obesity, are closely linked and often coexist. New approaches are needed to address the interrelated nature of these diseases. At Lilly, we ...